Answers are grounded in this paper and cite their sources.
The study reports on the psychometric properties of a new scale measuring neurobehavioral dysregulation, suggesting it may effectively capture impulsivity and emotional dyscontrol.
Objective The present study aimed to develop and validate a novel self-report measure of neurobehavioral dysregulation, a proposed transdiagnostic construct encompassing four symptom domains: impulsivity, affective lability, emotional dyscontrol, and explosivity. It was hypothesized that the newly developed questionnaire, entitled the Neurobehavioral Dysregulation Scale (NDS), would (a) fit a 4-factor model, (b) have acceptable internal consistency, and (c) demonstrate evidence for convergent and discriminant validity. Method A total of 60 items were developed (15 per domain) and reviewed by three neuropsychologists for expert validation. The NDS was administered electronically to a sample of 384 undergraduate students (Mage = 19.48, SD = 2.7) enrolled at a large public university in the Southern U.S. Confirmatory factor analysis (CFA) was conducted to test the hypothesized four-factor structure. Convergent and discriminant validity were assessed using the Neuro-Qol Emotional and Behavioral Dyscontrol – Short Form, the Patient Health Questionnaire-8 (PHQ-8), and the Generalized Anxiety Disorder-7 (GAD-7) questionnaires. Results The CFA supported the hypothesized four-factor model (CFI = .977, TLI = .976, RMSEA = .044). All subscales showed good internal consistency (αs = .92–.96). Convergent validity was supported by strong correlations with theoretically related Neuro-QoL Short Form (r = .801, p < .001). Discriminant validity was demonstrated by weaker correlations with PHQ-8 and GAD-7 scores (rs = .625-.644, ps < .001), indicating distinction from general mood symptoms. Conclusion The NDS demonstrates strong psychometric properties and may be a reliable and valid tool for assessing neurobehavioral dysregulation. Findings support its utility for research purposes, though further validation in clinical populations is warranted.
No takes yet. Share an insight, caveat, or question.
Fagle et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: